Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.97 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.97 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | BLM | P54132 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | POLB | P06746 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atropine SCHEMBL184594 | 1.00 | CHRM1 (0.97) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Hyoscyamine SCHEMBL28166772 | 1.00 | CHRM1 (0.97) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL41317 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL2812 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL17775090 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL17775091 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL19955084 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Hyoscyamine SCHEMBL41316 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL12264962 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL2813 | 0.99 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119318630-A | Atropine pharmaceutical composition | 苏州欧康维视生物科技有限公司 | 2025-01-17 | — | — | CN | claimed |
| US-20240335378-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | UNIV UTAH RES FOUND (US) | 2024-10-10 | — | — | US | claimed |
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | ELIXIR MEDICAL CORPORATION (US) | 2018-11-13 | — | — | US | claimed |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2017-05-04 | — | — | US | claimed |
| CN-105380947-A | Macrolide compound and use method thereof | ELIXIR MEDICAL CORP | 2016-03-09 | — | — | CN | claimed |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2015-12-10 | — | — | US | claimed |
| US-20130230571-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2013-09-05 | — | — | US | claimed |
| EP-2624834-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2013-08-14 | — | — | EP | claimed |
| EP-1480677-B8 | COMPOSITION FOR STABILIZING HYALURONIC ACID | CARL ZEISS MEDITEC SAS (FR) | 2012-05-23 | — | — | EP | claimed |
| WO-2012047813-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2012-04-12 | — | — | WO | claimed |
| US-20100086579-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2010-04-08 | — | — | US | claimed |
| WO-2009114010-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2009-09-17 | — | — | WO | claimed |
| EP-2026807-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHOD AND COMPOSITIONS | Universita' Degli Studi di Torino (IT) | 2009-02-25 | — | — | EP | claimed |
| US-20080234309-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2008-09-25 | — | — | US | claimed |
| WO-2007135574-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHOD AND COMPOSITIONS | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2007-11-29 | — | — | WO | claimed |
| EP-1480677-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2004-12-01 | — | — | EP | claimed |
| US-20030133986-A1 | Compositions for stabilizing poly (carboxylic acids) | TSAO FU-PAO (US) | 2003-07-17 | — | — | US | claimed |
| WO-2003043660-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
| CN-1174714-A | Whole set prescription for rehabilitation of hemiplegia | LIU HUANGQING (CN) | 1998-03-04 | — | — | CN | claimed |
| CN-1095924-A | A kind of compound injection for the treatment of soft tissue injury | WANG JIANSONG (CN) | 1994-12-07 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | CHRM2, CHRM1, CHRM5 | CHRM1 2/4885CHRM2 1/4885CHRM3 4/4885 |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | CHRM1 2/4885CHRM2 1/4885CHRM3 5/4885 |
| US-20240335378-A1 | COMPOSITIONS AND METHODS FOR TREATING SIALORRHEA | ACHE, MUC1, NEU3 | CHRM1 134/4885CHRM2 24/4885CHRM3 6/4885 |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | CHRM1 2/4885CHRM2 1/4885CHRM3 5/4885 |
| US-20080234309-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | CHRM1 2/4885CHRM2 1/4885CHRM3 5/4885 |
| US-20100086579-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | VIP, MIF, MYLK | CHRM1 1906/4885CHRM2 1578/4885CHRM3 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.